Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to. | April 12, 2023
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May. | April 12, 2023
01.04.2023 - 12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision and .
Phase 1a clinical trial of JNT-517 in healthy volunteers approaching completionBOSTON (BUSINESS WIRE) Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, will present preclinical data for its lead.